Trial Condition(s):
Hypertension, Pulmonary
A study to understand the treatment patterns in patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension during a switch of treatment to Adempas in real-life clinical practice (CAPTURE)
Bayer Identifier:
17983
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life clinical practice.
In addition, this study will describe patient demographics and reason for switching
Inclusion Criteria
- Female and male adult patients diagnosed with PAH or inoperable/recurrent/persistent CTEPH who have been switched from a PH treatment (i.e. Endothelin Receptor Antagonist(ERAs), Phosphodiesterase-5 inhibitor(PDE5i) or Prostacyclin Analog (PCA) to Adempas
Exclusion Criteria
- Patients participating in an investigational program with interventions outside of routine clinical practice - Patients who have not switched their therapy from an Endothelin Receptor Antagonist (ERA) or Prostacyclin Analog (PCA) but received Adempas purely as an add-on therapy
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Germany | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Japan | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Canada | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Belgium | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Sweden | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Turkey | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Colombia | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Retrospective chart review of patients with PAH or inoperable/persistent/recurrent CTEPH who transition their PH treatment to Adempas
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Starting DoseTimeframe: Up to a total of 8 weeks of titration period
- Dose IncrementsTimeframe: Up to a total of 8 weeks of titration period
- Final DoseTimeframe: Up to a total of 8 weeks of titration period
Additional Information
Copyright © Bayer
Powered by
